His research ties Endocrinology and Vasopressin together. His Endocrinology study frequently draws connections to other fields, such as Oxytocin. His research is interdisciplinary, bridging the disciplines of Internal medicine and Oxytocin. As part of his studies on Internal medicine, Edward A. Sausville often connects relevant areas like Lung cancer. Edward A. Sausville conducted interdisciplinary study in his works that combined Lung cancer and Cancer research. He combines Cancer research and Genetics in his research. As part of his studies on Genetics, he often connects relevant areas like Vasopressin. Edward A. Sausville performs integrative Cell culture and Molecular biology research in his work. Edward A. Sausville integrates many fields, such as Molecular biology and Gene, in his works.
His Toxicity study is within the categories of Phases of clinical research and Neutropenia. As part of his studies on Neutropenia, Edward A. Sausville often connects relevant subjects like Toxicity. Many of his studies on Gene involve topics that are commonly interrelated, such as Cyclin B. In his research, he performs multidisciplinary study on Cyclin B and Cyclin-dependent kinase. He merges Cyclin-dependent kinase with Cyclin D1 in his study. Cyclin D1 and Cell are commonly linked in his work. Cell is closely attributed to Cell cycle in his work. He integrates many fields, such as Cell cycle and CDK inhibitor, in his works. His study on CDK inhibitor is mostly dedicated to connecting different topics, such as Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents
Julian Adams;Vito J. Palombella;Edward A. Sausville;Jill Johnson.
Cancer Research (1999)
Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells
Bradley A. Carlson;Marja M. Dubay;Edward A. Sausville;Leonardo Brizuela.
Cancer Research (1996)
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Adrian M. Senderowicz;Edward A. Sausville.
Journal of the National Cancer Institute (2000)
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Ashraf Badros;Dianna Weikel;Andrew Salama;Olga Goloubeva.
Journal of Clinical Oncology (2006)
Novel Proteasome Inhibitor PS-341 Inhibits Activation of Nuclear Factor-κB, Cell Survival, Tumor Growth, and Angiogenesis in Squamous Cell Carcinoma
John B. Sunwoo;Zhong Chen;Gang Dong;Ning Yeh.
Clinical Cancer Research (2001)
UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53
Qizhi Wang;Saijun Fan;Alan Eastman;Peter J. Worland.
Journal of the National Cancer Institute (1996)
Identification of Small Molecule Inhibitors of Hypoxia-inducible Factor 1 Transcriptional Activation Pathway
Annamaria Rapisarda;Badarch Uranchimeg;Dominic A. Scudiero;Mike Selby.
Cancer Research (2002)
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Edward A. Sausville;Angelika M. Burger.
Cancer Research (2006)
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
Sudhir B Kondapaka;Sheo S Singh;Girija P Dasmahapatra;Edward A Sausville.
Molecular Cancer Therapeutics (2003)
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
A M Senderowicz;D Headlee;S F Stinson;R M Lush.
Journal of Clinical Oncology (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: